Navigation Links
Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
Date:3/13/2008

be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Cellectis SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Cellectis SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the prospectus approved by the French Autorite des Marches Financiers ("AMF") on January 22nd, 2007 under visa number 07-023, available on the websites of the AMF ( http://www.amf-france.org) and Cellectis (http://www.cellectis.com)


'/>"/>
SOURCE Cellectis SA
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
2. DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development
3. Time Domain Showcases Precision Location Capability of Ultra Wideband PLUS Product Line at HIMSS 2008
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...24/PRNewswire/--Twomoreprestigiousuniversitieshave...oardandcareerssiteforlifescienceprofessionals. ,...fthejobboard,joining28othermajorlifesciencetrainin...ter.com ,isonlyforpost-graduatesinthelifesciences....Internet,BioCareerCenteristheonlyonethatserveslife...
(Date:11/24/2009)...swire-FirstCall/--Sigma-AldrichCorporation(Nasdaq:...uesday,December1stat1:45PMGMTinLondon,7:45AMUS/CST...ertheInternetavailableat http://inve s tor.sig ...contoaccessthisfile. ,, AboutSigma-Aldrich: ...ycompany.Itschemicalandbiochemicalproductsandkitsa...
(Date:11/24/2009)...swire-Asia/--NODPharmaceuticalsInc.announced,theUS...applicationfor,itsnano-particleoraldeliveryorNODte...proachtoincorporatepeptidesor,proteinsintobio-adhe...rwiseadministeredasinjections.NODtechnologyisaplat...rdrugssuchasinsulin,interferon,growthhormone,exen...
(Date:11/24/2009)...wire/--BlueMarbleEnergyCorp.announcedtodaythatthec...wererecentlyawarded$2millionbyWashingtonState,sCom...publicpartnershiptoconstructthestate,sfirstspecial..."Thisinvestmentwillsignificantlyspeedthedevelopmen...ounty,"saidBlueMarbleEnergyCEOKellyOgilvie."Weareg...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...ific (NYSE: BSX ) today announced special items ...uarter. The Company plans to release its first qu...ompany disclosed last month, the Court of Appeals ...s decision that Johnson & Johnson,s (J&J) ...e Boston Scientific,s patent and that the patent i...
...gnostics,Incorporated (NYSE: DGX ) today announc...osed federal government investigation related to c...anufacturing subsidiary closed,voluntarily in 2006... since,its investigation began in 2004. , Ques...civil investigation.,While the company disagrees w...
...announced today that it,has completed the formatio...ment its existing group of Senior Advisers. NexBi... of DAS181 (Fludase(R)), an investigational drug,c...Bio throughout the clinical,development of this no...ced,product development to address the threat of a...
Other Biology Technology:Boston Scientific Announces First Quarter Special Items 2Boston Scientific Announces First Quarter Special Items 3Boston Scientific Announces First Quarter Special Items 4Boston Scientific Announces First Quarter Special Items 5Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 3NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 4
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Prostate cancer gives a new outlook on life 58853 1Prostate cancer gives a new outlook on life 58853 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 1University of Washington receives 2425 million to create Northwest Genomics Center 10256 2University of Washington receives 2425 million to create Northwest Genomics Center 10256 3University of Washington receives 2425 million to create Northwest Genomics Center 10256 4Focused Radiation Protects Tumor Patients Brain Function 58850 1Focused Radiation Protects Tumor Patients Brain Function 58850 2
... in response to higher global temperatures may be ...count plants, ability to adjust to changing condit...onal Laboratory. , In a Perspectives paper publish...tes ORNL findings suggesting that about 9 percent ... the acclimation of plants included in the model. ...
...bage-eating moth may one day provide a safer, targ...y, researchers say. , , They compared the abilit... transposons, to insert themselves into a cell,s D...e cell resistant to damage from radiation therapy....o 10 times better than the other circular pieces o...
...nia, Los Angeles have defined conditions associate...n almost a third of breast cancer survivors, accor...ncer Research. , The key to their fatigue stems ...hese studies identify a biological basis for persi...ted by inflammation," said Michael Irwin, M.D., di...
Other Biology News:Plants' role in global warming re-examined 2Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Inflammation markers identify fatigue in breast cancer survivors 2
EDTA Solution (pH 8.0) (0.5 M) from BioVision
Rat Anti-Mouse Limitin Monoclonal Antibody, Unconjugated, Clone 183727 from R&D Systems
Normal Human Serum from CHEMICON
Human HGF, Unconjugated from R&D Systems
Biology Products: